Blueprint Medicines Corp (NASDAQ: BPMC) has reported earnings for its first fiscal quarter (ending March 31) of $1.45 versus a loss $-2.15 for the same period a year ago. This performance was $2.66 better than the consensus estimate of $-1.21. For the latest four quarters through March 31, E.P.S. were $-4.76 versus $-9.71 for the same period a year ago.
Recent Price Action
Blueprint Medicines Corp (NASDAQ: BPMC) stock enjoyed a major increase of 12.8% on 5/2/24. The shares closed at $107.00. Moreover, trading volume in this advance was exceptionally high at 258% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 16.0% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, BPMC is expected to be a modest Value Builder.
Blueprint Medicines has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Blueprint Medicines has a very low Appreciation Score of 1 but a very high Power Rating of 98, resulting in the Neutral Value Trend Rating.
Rating Review
In light of this new information and very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment